Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer.

Autor:	Yang Q; Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China; Department of Pharmacy, School of Medicine, Shaanxi Energy Institute, Xianyang 712000, China., Liu DZ; Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China., Liu M; Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China., Ji QF; Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China., Mei QB; Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China., Cheng Y; Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China. Electronic address: chengying86128@126.com., Zhou SY; Department of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China. Electronic address: zhousy@fmmu.edu.cn.
Jazyk:	angličtina
Zdroj:	Journal of pharmaceutical sciences [J Pharm Sci] 2021 Feb; Vol. 110 (2), pp. 876-887. Date of Electronic Publication: 2020 Nov 07.
DOI:	10.1016/j.xphs.2020.11.005
Abstrakt:	Prostate cancer is the most common malignant tumor with bone metastasis, and there is still no ideal treatment for bone metastasis of prostate cancer. In this study, a pH and GSH dual sensitive calcium phosphate-polymer hybrid nanoparticle (DTX@Cap/HP) was prepared to co-deliver zoledronate (ZOL) and docetaxel (DTX) to treat bone metastasis of prostate cancer. DTX@Cap/HP exhibited high bone binding affinity and released more DTX and ZOL in acidic and high GSH concentration environment. A large amount of DTX@Cap/HP was uptaken by PC-3 cell in acidic medium than that in neutral medium. DTX@Cap/HP obviously reduced PC-3 cell proliferation and bone lesion in in-vitro 3D model of bone metastases of prostate cancer. Besides, DTX@Cap/HP also exhibited stronger anti bone metastases of prostate cancer activity in vivo as compared with the same dose of DTX + ZOL, which resulted from the co-delivery of DTX and ZOL to bone metastases of prostate cancer by DTX@Cap/HP and the synergistic effects of DTX and ZOL. DTX@Cap/HP has great potential in the treatment of bone metastases of prostate cancer. (Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu